Shared epitope and anti-cyclic citrullinated peptide antibodies: Relationship with age at onset and duration of disease in rheumatoid arthritis

Journal of Rheumatology

Volumn 36, Issue 5, 2009, Pages 1085-1086

  Varadé, Jezabel ^a   Loza Santamaría, Estíbaliz ^a   Fernández Arquero, Miguel ^a   Lamas, Jose Ramón ^a   Figueredo, Maria De Los Ángeles ^a   Jover, Juan Angel ^a   De La Concha, Emilio Gómez ^a   Rodríguez, Luis ^a   Urcelay, Elena ^a   Fernández Gutiérrez, Benjamín ^a   Martínez Doncel, Alfonso ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ARGININE; CITRULLINATED PEPTIDE ANTIBODY; ENZYME; EPITOPE; HLA DR ANTIGEN; PEPTIDYL ARGININE DEIMINASE DERIVATIVE; UNCLASSIFIED DRUG; ANTIIDIOTYPIC ANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; HLA-DRB1 ANTIGEN;

DISEASE DURATION; DISEASE SEVERITY; FOLLOW UP; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENETICS; LETTER; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN MODIFICATION; RHEUMATOID ARTHRITIS; AGE; CROSS-SECTIONAL STUDY; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; IMMUNOLOGY; MALE; MIDDLE AGED; ONSET AGE; TIME;

AGE FACTORS; AGE OF ONSET; ANTIBODIES, ANTI-IDIOTYPIC; ARTHRITIS, RHEUMATOID; CROSS-SECTIONAL STUDIES; EPITOPES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-DR ANTIGENS; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; TIME FACTORS;

EID: 67449104845     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080735     Document Type: Letter

References (10)

1. Yamada R, Suzuki A, Chang X, Yamamoto K. Peptidylarginine deiminase type 4: identification of a rheumatoid arthritis-susceptible gene. Trends Mol Med 2003;9:503-8.
2. Barton A, Bowes J, Eyre S, Symmons D, Worthington J, Silman A. Investigation of polymorphisms in the PADI4 gene in determining severity of inflammatory polyarthritis. Ann Rheum Dis 2005;64:1311-5.
3. Martinez A, Valdivia A, Pascual-Salcedo D, et al. PADI4 polymorphisms are not associated with rheumatoid arthritis in the Spanish population. Rheumatology 2005;44:1263-6.
4. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004;63:1090-5.
5. Wagner U, Kaltenhauser S, Sauer H, et al. HLA markers and prediction of clinical course and outcome in rheumatoid arthritis. Arthritis Rheum 1997;40:341-51.
6. Deighton C, Criswell LA. Recent advances in the genetics of rheumatoid arthritis. Curr Rheumatol Rep 2006;8:394-400.
7. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
8. Meyer O, Nicaise-Roland P, Santos MD, et al. Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis. Arthritis Res Ther 2006;8:R40.
9. Ronnelid J, Wick MC, Lampa J, et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005;64:1744-9.
10. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes RE, de Vries RR. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 2006;54:1117-21.